# Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)

> **NCT04055038** · PHASE2,PHASE3 · UNKNOWN · sponsor: **Blokhin's Russian Cancer Research Center** · enrollment: 164 (estimated)

## Conditions studied

- Ovarian Cancer
- Ovarian Neoplasms
- Serous Adenocarcinoma
- BRCA1 Mutation
- BRCA2 Mutation
- Chemotherapy

## Interventions

- **DRUG:** Platinum-Based Drug
- **DRUG:** Conventional chemotherapy

## Key facts

- **NCT ID:** NCT04055038
- **Lead sponsor:** Blokhin's Russian Cancer Research Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-09-01
- **Primary completion:** 2021-09-01
- **Final completion:** 2022-01-01
- **Target enrollment:** 164 (ESTIMATED)
- **Last updated:** 2019-08-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04055038

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04055038, "Efficacy of Platinum-based Chemotherapy in Platinum-resistant Ovarian Cancer) (EPITOC)". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04055038. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*